MAO-B inhibitor know-how
Back to the pharm Peter A. LeWitt, MD Farmers have a saying that "you don't need to know how the corn grows, just the know-how to keep it growing." Similarly, the know-how for physicians to make effective use of a drug does not always require detailed pharmacologic understanding-but it helps to know more than what appears in its advertising or product information. This is especially true for Parkinson disease (PD) therapeutics with monoamine oxidase-type B (MAO-B) inhibitors. This class of drugs has returned to the PD spotlight with recent developments regarding the possibility of cognitive enhancement (with safinamide 1 [Merck Serono; Geneva, Switzerland]) and with claims of neuroprotection (with rasagiline 2 [Azilect; Teva Neuroscience, Petah Tikva, Israel]). Disease modification also has been the theme of prior studies with the MAO-B inhibitors selegiline and lazabemide. 3, 4 Though both selegiline and rasagiline are widely used in PD for symptomatic therapy, this and other applications for MAO-B inhibitors have not been without controversy, and there are many gaps in understanding their basic and clinical pharmacology. Sorting out facts from hype can be a challenge for busy clinicians.
Take, for example, their dosing. The recommended intake for selegiline is 5 mg twice daily, 5 while product information for rasagiline describes its starting dose as 0.5 mg/day, increasing to 1 mg/day ". . . if a sufficient clinical response is not achieved." 6 After oral intake, both selegiline and rasagiline are cleared rapidly, with little parent compound remaining by only a few hours later. However, since both drugs bind irreversibly to MAO-B, their plasma clearance half-life would seem to be of little consequence because their enzymatic inhibition lingers for much longer. The extended duration of MAO-B blockade has implications for how these drugs can be used. For example, after a single dose of selegiline, PET studies in the human brain showed that full recovery of MAO-B required greater than 4 weeks 7 due to the slow synthesis of new enzyme replacing drug-bound MAO-B. As a clinical correlate of its extended action, a continuing symptomatic effect of selegiline (deprenyl) could be detected in Unified PD Rating Scale (UPDRS) testing in the DATATOP study, 8 a clinical trial investigating neuroprotection. DATATOP found that persisting symptomatic antiparkinsonian actions of selegiline were evident even up to 6 weeks beyond its discontinuation. 9 Based on this evidence, daily intake of an irreversible MAO-B inhibitor would seem to be unnecessary. Only if these drugs had additional pharmacologic properties beyond their MAO-B inhibition would daily dosing seem to be appropriate. Both rasagiline and selegiline have properties counteracting neurodegeneration in laboratory experiments, but the pertinence of these observations to PD remains to be demonstrated. 3, 10 What do we know about the effectiveness of MAO-B inhibitors as symptomatic therapy for PD? In the brain, MAO-B is the major enzymatic step for converting dopamine to its inactive catabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid (HVA). Inhibition of MAO-B retards the otherwise rapid turnover of striatal dopamine, 11 resulting in accumulation of this neurotransmitter. For a patient with PD, blocking the catabolism of endogenous dopamine provides symptomatic relief through enhanced neurotransmission. Elevating endogenous dopamine concentrations might seem to be a practical alternative to dopaminergic replacement therapy. However, the magnitude of antiparkinsonian effect derived from a MAO-B inhibitor often does not meet the needs of a patient with PD who is starting to experience discomfort or disability. A Movement Disorder Society (MDS) Task Force on EvidenceBased Medicine, reviewing the evidence for monotherapy with selegiline as a symptomatic PD therapy, concluded that in one of the published studies there was no difference between selegiline and placebo in clinical outcome, and that the other five studies reported only small benefits from selegiline. 12 With respect to rasagiline monotherapy, however, the MDS Task Force designated this drug MAO-B inhibitor as efficacious for PD based on the results of a single study. 13 However, like selegiline, the clinical effects of rasagiline (at either 0.5 or 1 mg/day) amounted to only small changes in UPDRS scores. Given the limited symptomatic improvements offered by these MAO-B inhibitors (in contrast to dopaminergic therapy), it is puzzling why this class of drugs so often is recommended as first-line PD treatment. [14] [15] [16] [17] [18] For treatment of advanced PD as well, the MAO-B inhibitor story is not much different. The pharmacologic principle involved in therapeutics of motor fluctuations is to block the breakdown of dopamine produced from each dose of levodopa. In targeting the dose-bydose wearing-off of levodopa benefit, MAO-B inhibitors join two other pharmacologic options also intended to achieve a similar goal (sustained-release levodopa and catechol-O-methyltransferase [COMT] inhibition). These levodopa extension strategies can be combined for extra advantage, as shown by results from coadministering selegiline with the COMT inhibitor entacapone. 19 However, most clinical experience has shown that selegiline adjunctive therapy, like sustained-release levodopa and COMT inhibitors, offers only modest gains. For example, an early selegiline clinical trial found that adding this drug resulted in only a small increase of "good time" in patients with PD with motor fluctuations and no improvement in the quality of the "on" state. 20 Another study reported that selegiline failed to enhance "on" time (although severity of "off" states tended to be diminished). 21 In evaluating these and other clinical trials, the MDS Task Force's evidence-based review 12 regarded the available evidence as insufficient for concluding that selegiline was efficacious in treating motor fluctuations.
The MDS Task Force evidence-based review did not include two subsequent clinical trials that investigated control of wearing-off responses with selegiline in an orally disintegrating tablet (Zydis . With this formulation, these multicenter clinical trials (utilizing similar patient populations and identical study designs) showed surprisingly disparate results. One study in patients with PD with motor fluctuations found that selegiline provided a significant improvement in "off" time (a 9% reduction), 22 whereas the other detected no change. 23 When the data from both trials were merged, 23 the combined magnitude of the selegiline effect led to less improvement in "on" time than would be typically derived from adjunctive use of entacapone. 24 Investigations with rasagiline provided comparable results in patients with PD with wearing-off responses. In one placebo-controlled rasagiline study in patients with PD with wearing-off responses, their improvement in "on" time was less than 1 hour per day. 25 Another clinical trial found that rasagiline reduced mean daily "off" time by approximately 0.8 hours, as compared to placebo. 26 This effect was comparable to the improvement observed in the study's entacapone treatment arm. As with COMT inhibitors and sustained-release levodopa, the relatively small gains provided by MAO-B inhibitors in treating wearing-off responses has emphasized the need for better treatments than what these current therapeutic options can offer.
Another MAO-B inhibitor controversy swirls around the amphetamine byproducts of selegiline catabolism. Though produced only in small quantities, these metabolites have long been a topic of speculation about a possible role in selegiline's adverse effect profile. Since rasagiline is not metabolized to amphetamine derivatives, one of its marketing attributes has been a differentiation from selegiline on this basis. Amphetamines are well known for undesirable pharmacologic actions such as appetite suppression and interference with sleep. However, as its product information makes clear, selegiline's adverse effect profile 5 is actually similar to that of rasagiline 6 and neither sleep disturbance nor other typical stimulant drug actions are mentioned. The pharmacology of selegiline provides an explanation why amphetamine effects are not especially bothersome: selegiline undergoes metabolic conversion to amphetamine L-isomers, whose actions at monoaminergic nerve terminals are considerably less than effects of the corresponding D-isomers. Hence, conventional oral doses of selegiline do not produce much in the way of pharmacologically active amphetamine metabolites.
One marketed selegiline product has also taken aim at amphetamine metabolites in order to distinguish itself from conventional selegiline in oral tablet form. With Zydis ® selegiline (Zelapar ® ), which is absorbed through the buccal mucosa, much of the drug escapes first-pass hepatic metabolism. The result is lower concentrations of L-amphetamine and L-methamphetamine than quantities of these metabolites derived from equipotent doses of oral selegiline tablets. 27 While this would be an appealing strategy if the amphetamine metabolites caused side-effects,
Speculation has also focused on the possibility that L-amphetamine and L-methamphetamine metabolites of selegiline might impart toxicity to dopaminergic neurons. The basis for these concerns is that, under experimental conditions in the rat brain, high doses of D-methamphetamine damage dopaminergic neurons through a mechanism generating oxidative stress. 28 Despite this possibility, there has not been demonstration of neurotoxicity in the human substantia nigra after continued exposure to the low L-methamphetamine concentrations arising from regular selegiline use. If in fact this metabolite was damaging to dopaminergic neurons, an expected consequence from chronic use of selegiline might be worsening of parkinsonism (which has not been observed in controlled clinical trials). Another insight into this question comes from a clinical study that directly analyzed long-term outcomes from repeated and chronic high-dose D-methamphetamine exposure. Neurologic examination of a group of D-methamphetamine abusers (whose regular use of this drug on a frequent basis averaged 10 years) revealed no instance in which parkinsonian features evolved (P.A. LeWitt, personal observation). 29 Furthermore, their PET scan markers of putaminal dopamine transporter sites showed only a small reduction in this brain biomarker for dopaminergic nerve terminals as compared to age-matched controls.
Another long-standing question regarding MAO-B inhibitors is whether available evidence provides any justification for endorsing them as neuroprotective therapy. While their approved use is for symptomatic treatment of PD, the clinical pharmacology of MAO-B inhibitors has been closely linked to an ongoing quest for a neuroprotective PD treatment. 3, 10 Widely held opinions expressed in lectures, texts, and treatment algorithms [14] [15] [16] [17] [18] have sometimes endorsed this notion as if proven. The rationale for several MAO-B inhibitor clinical trials (with selegiline, lazabemide, and rasagiline) were predicated on the oxidative stress hypothesis for PD. 3 In essence, this speculation holds that free radical damage to substantia nigra dopaminergic neurons is a consequence from MAO-Bmediated catabolism of dopamine, which results in generation of hydrogen peroxide that next reacts to form the hydroxyl radical. By means of MAO-B inhibition, the therapeutic strategy has been to divert dopamine catabolism to pathways not generating the neurotoxic oxyradicals. Considerable pharmacologic evidence from animal research supported this hypothesis and its eventual extrapolation to clinical research as a possible means to reduce oxidative stress in substantia nigra neurons. 30 However, results from a clinical study told a different tale. For selegiline-treated patients with PD participating in the DATATOP study, CSF specimens collected were analyzed for the dopamine metabolite HVA. 31 HVA arises only by the oxidative deamination of dopamine through MAO (whether through MAO-B or by the type A isoform of the enzyme). Since CSF HVA concentration was diminished by only an estimated one-fifth of its baseline value, these results indicated that chronic selegiline use in the DATATOP study did not actually test the value of blocking oxyradical generation from the turnover of dopamine. However, even if the original rationale for neuroprotection from MAO-B inhibition was faulty, both selegiline and rasagiline have other pharmacologic properties that, in the laboratory, confer apparent neuroprotective effects unrelated to binding to MAO-B. 32, 33 Whether any of these properties is relevant either to the pathogenesis of PD or to neuroprotection remains to be demonstrated.
Going back more than 2 decades, the first investigations of neuroprotection from MAO-B inhibition were the DATATOP study 8, 9 and a similar clinical trial conducted by Tetrud and Langston. 34 In their influential 1989 publications (which also fostered considerable controversy), each study reported that selegiline delayed the progression of PD in its early stages, as judged by various clinical measures. The original conclusions from the DATATOP study needed to be modified when subsequent analysis determined that the initial impression of selegiline's protective actions could not be differentiated from its confounding symptomatic effects. 9 Other studies investigating disease modification from selegiline also had a similar challenge. 35, 36 For these and other reasons, the MDS Task Force on Evidence-Based Medicine commented that the several neuroprotection trials with selegiline provided insufficient evidence for deciding whether this drug offered a neuroprotective effect. 12 The Cochrane Database of Systematic Reviews reached similar conclusions. 37 One approach attempting to dissect symptomatic effects from disease modification has been the delayedstart study design. For a neuroprotection study conducted with the MAO-B inhibitor rasagiline (the TEMPO study 13 ), outcomes from initial use of rasagiline at 2 mg/day were compared to results in patients with PD delayed 6 months before the start of drug treatment. The results seemed promising: over 6 months, the group delayed at starting rasagiline did not catch up to the extent of improvement experienced by the group initially treated with rasagiline. Although intriguing for its implication of a possible neuroprotective effect, the treatment effect between the two early and delayed start groups differed by slightly more than two UPDRS units, a relatively small clinical change. Commenting on the TEMPO study results, the Quality Standards Subcommittee of the American Academy of Neurology observed that ". . . the additional symptomatic treatment (dopaminergic therapy) and possible symptomatic effect of rasagiline itself confounds the interpretation of whether this represents a neuroprotective effect." 38 The delayed-start study design used in TEMPO has also found other skeptics. 39 This trial design was also used in a recently completed clinical trial of 1,176 patients with early PD randomized to treatment with either placebo or rasagiline at 1 or 2 mg/day (the ADAGIO study). 40 In findings reported for the 1 mg/day group, 2,41 the magnitude of improvement derived from early start of rasagiline, as compared to the delayed start group, was 1.7 UPDRS units at the 72-week endpoint (representing 36 weeks of additional rasagiline treatment). These results are consistent with the earlier TEMPO study findings that also suggested disease modification. 13 However, the small clinical improvements noted in both studies need to be contrasted with typical rate of progression in early PD, whose mean annual change ranges from 6.31 to 10.46 UPDRS units. 42 A puzzling finding in the ADA-GIO study is that, unlike the outcome for the 1 mg/day treatment group, the delayed-start results indicated no apparent neuroprotective effect in subjects randomized to rasagiline at 2 mg/ day.
2,40, 41 The results of this study, already presented at two neurologic meetings, await publication and critical review as to whether rasagiline offers neuroprotection and to a clinically meaningful extent. Any insight into slowing of disease progression is welcome and raises hopes that the pathogenesis of this disorder is within the grasp of emerging PD therapeutics. Clinicians with the option of prescribing MAO-B inhibitors as possible neuroprotective therapies will need to exercise their critical review of study results so that their choices will not be swayed by marketing claims or wishful thinking.
And so, given a pharmacologic perspective on what we know and do not know about MAO-B inhibitors, do we really have the know-how for their effective use? In addition to the questions posed above, other important matters with these commonly used drugs await better understanding:
Are MAO-B inhibitors effective at controlling motor fluctuations? As discussed above, some evidence suggests that the available MAO-B inhibitors can be effective for extending dopaminergic effect in patients with wearing-off responses. Usefulness for other types of motor fluctuations such as start hesitancy and unpredictable "off" states has not been established, however. The only clue in this regard came from the DATATOP study, 8, 9 which showed that treatment with selegiline decreased the risk for patients to develop freezing of gait.
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Are the tyramine-content dietary restrictions imposed on rasagiline use really necessary? Tyramine-induced hypertension and tachycardia ("cheese effect") is a risk accompanying the use of MAO type-A inhibitors but is not known to occur as a consequence of selective MAO-B blockade. Nevertheless, this hypothetical concern appears prominently in the product information for rasagiline. 6 Although there have been no reported instances of serious tyramine-induced hypertension or tachycardia, the Food and Drug Administration mandates a warning to patients, together with a somewhat complicated list of foods and beverages to be avoided. A recent clinical study investigated this risk in patients with PD under treatment with 0.5-2 mg of rasagiline daily and receiving tyramine challenges of 50 -75 mg. Careful monitoring showed that tyramine exposure was well tolerated and caused no significant blood pressure or heart rate changes. 44 On this basis, it would seem that the putative risks from dietary tyramine intake are overstated. However, it remains for regulatory authorities to decide whether a change in rasagiline's labeling can be made. Given the pharmacologic similarities between rasagiline and selegiline, dietary restrictions imposed on one drug but not the other seems an arbitrary decision. Does selegiline pose the risk for lethal outcomes? A large prospective randomized clinical trial carried out in the UK during the 1990s reported that a cohort of patients with PD receiving selegiline plus levodopadecarboxylase inhibitor experienced significantly more deaths than patients receiving a regimen of just levodopa-decarboxylase inhibitor. 45 Despite further investigation into causes of death for the study participants, no answer (or even a biologically plausible explanation) could be determined for the excess mortality associated with selegiline treatment. 46 Several other prospective studies investigating this question, such as the DATATOP trial, 47 have not confirmed a similar relationship between use of this drug and increased risk for death.
Several other questions await further pharmacologic understanding with respect to PD and treatment with selegiline and rasagiline. The history of MAO-B inhibitors is an elegant story of drug development 48 and clearly, many patients achieve benefit from their use. 49 But we still have a lot more to learn.
